InMode Ltd. (INMD)
| Market Cap | 926.94M |
| Revenue (ttm) | 374.64M |
| Net Income (ttm) | 87.19M |
| Shares Out | 63.36M |
| EPS (ttm) | 1.36 |
| PE Ratio | 10.77 |
| Forward PE | 10.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,141,032 |
| Open | 14.68 |
| Previous Close | 14.81 |
| Day's Range | 14.37 - 14.81 |
| 52-Week Range | 12.72 - 16.74 |
| Beta | 1.93 |
| Analysts | Hold |
| Price Target | 14.33 (-2.05%) |
| Earnings Date | Jul 29, 2026 |
About INMD
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. The ... [Read more]
Financial Performance
In 2025, InMode's revenue was $370.50 million, a decrease of -6.16% compared to the previous year's $394.82 million. Earnings were $93.83 million, a decrease of -48.24%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for INMD stock is "Hold." The 12-month stock price target is $14.33, which is a decrease of -2.05% from the latest price.
News
DOMA Perpetual says InMode buyout proposal ‘materially undervalues’ company
DOMA Perpetual Capital Management, a significant stockholder of InMode (INMD), sent a letter to the Board of Directors of InMode. The letter states: ” As of the date of this…
DOMA PERPETUAL CAPITAL MANAGEMENT STRONGLY OPPOSES INMODE BUYOUT AS PROPOSED; PLANS TO VOTE AGAINST DEAL
DOMA ASSERTS THAT THE $16.20 PER SHARE OFFER MATERIALLY UNDERVALUES INMODE AND ITS LONG-TERM POTENTIAL DOMA BELIEVES THE BID EXPLOITS THE DEPRESSED VALUATIONS CREATED BY YEARS OF CEO-LED UNDERPERFORMA...
InMode confirms receipt of unsolicited $16.20 per share takeover proposal
InMode (INMD) announced that, on June 17, its board of directors received an unsolicited proposal from M.N. Business Strategy, Ltd. to acquire through a merger all of the outstanding ordinary…
InMode Confirms Receipt of Unsolicited Proposal
YOKNEAM, Israel, June 24, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) (the "Company") today announced that, on June 17, 2026, its Board of Directors (the "Board") received an unsolicited proposal...
InMode Transcript: Jefferies Global Healthcare Conference 2026
Management expects a flat revenue year amid market stabilization, with margin pressure from product mix and geographic shifts. New product launches, a specialized sales approach, and ongoing clinical studies aim to drive future growth, while capital allocation remains flexible.
InMode names Moshik Itzkovich as CFO, succeeding Yair Malca
InMode (INMD) announced the appointment of Dr. Shlomo Nass as Chairman of the company’s Board of Directors and Moshik Itzkovich as CFO, effective immediately. Moshik has held senior finance roles…
InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer
YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of D...
InMode to Present at Upcoming Investor Conferences and Events
YOKNEAM, Israel, May 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conf...
InMode price target lowered to $14 from $17 at Baird
Baird lowered the firm’s price target on InMode (INMD) to $14 from $17 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results and…
InMode price target lowered to $19 from $21 at Barclays
Barclays lowered the firm’s price target on InMode (INMD) to $19 from $21 and keeps an Overweight rating on the shares.
InMode reports Q1 adjusted EPS 25c, consensus 30c
Reports Q1 revenue $82.02M, consensus $79.86M. “While the macroeconomic environment remains challenging, our total revenue this quarter reached our expectations, however our profitability was lower th...
InMode sees FY26 adjusted EPS $1.33-$1.38, consensus $1.45
Sees FY26 revenue $365M-$375M, consensus $370.04M. Non-GAAP gross margin between 74%-76%.
InMode CFO Yair Malca steps down
Yair Malca has stepped down from his role as CFO, effective May 5. To support a smooth transition, Malca will remain engaged with the company in a consulting capacity for…
InMode Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 5% year-over-year to $82M, led by U.S. strength, while gross margin declined due to product mix and higher expenses. Guidance for 2026 remains steady, with ongoing share buybacks and exploration of M&A as market competition intensifies.
InMode Earnings release: Q1 2026
InMode released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
InMode Slides: Q1 2026
InMode has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for...
Weight-loss revolution sparks new appetite for aesthetics firms
Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...
InMode Transcript: 25th Annual Needham Virtual Healthcare Conference
Q1 growth was driven by new product launches, but gross margins declined due to higher costs and increased competition. The company is expanding its product portfolio and international presence, while ongoing clinical studies and regulatory submissions target future growth. Guidance for 2026 remains cautious.
InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd.
InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer an...
InMode Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Operations face ongoing disruptions in Israel, with manufacturing at 60% capacity and logistics strained. Over $600 million has been returned via buybacks, while M&A targets focus on complementary tech and Asia. Growth is expected to resume in 2027, supported by new products and organizational restructuring.
InMode announces new share repurchase program
InMode (INMD) announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the company’s total shares outstanding, representing approximately 6.38...
InMode Announces New Share Repurchase Program
YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a n...
InMode Transcript: Barclays 28th Annual Global Healthcare Conference
After two years of decline, expectations are for a flat top line in 2026, with organizational restructuring and new product launches aimed at supporting recovery. Margin pressures persist due to laser commoditization, but growth in new verticals and a focus on North America are key strategies.